BC Innovations | Jun 3, 2010
Distillery Therapeutics

Indication: Endocrine disease

Endocrine disease Diabetes Peptidylprolyl isomerase F (PPIF; cyclophilin D); pancreatic and duodenal homeobox 1 (PDX1; IPF1) Mouse studies suggest that inhibiting cyclophilin D in diabetic patients with dysfunctional PDX1 could help treat the condition. Genetic...
BC Innovations | May 28, 2009
Targets & Mechanisms

New angiogenesis targets

An international collaboration among researchers at the Karolinska Institute , Discovery Genomics Inc. and AngioGenetics AB has produced a set of previously unknown and potentially druggable targets in angiogenesis along with several matching antiangiogenic compounds. 1...
BC Innovations | May 21, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Cyclophilin A (CYPA; peptidylprolyl isomerase A; PPIA) Studies in mice suggest that inhibiting CYPA could be useful for...
BC Innovations | Oct 2, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Cyclophilin D (CYPD; peptidylprolyl isomerase D; PPID) Studies in vitro and in mice suggest that inhibiting CYPD...
Items per page:
1 - 4 of 4